Venus Remedies launches US Patent projected product ‘ELORES’ in India

18 Jan 2013 Evaluate

Venus Remedies has launched CSE 1034, under the brand name ‘ELORES’, a novel Antibiotic Adjuvant Entity (AAE) to combat antimicrobial resistance caused by MDR, ESBL producing strains. The product was launched at Manthan 2013, a seminar-cum-workshop organized by ‘Venus Medicine Research Centre’ (VMRC).

ELORES is designed specifically to target growing bacterial resistance mechanisms. It has a unique profile of action which gives it an edge over all the existing therapies. This unique antibiotics adjuvant entity creates a synergistic effect due to its activity on AMRINGER (Acquired Multiple Resistance in Gram Negative Enterococci and Rods) which stops development and spread of bacterial resistance.

This product is effective against Metallo betalactamases (MBL) producing pathogens which are not susceptible to most of the existing antibiotics. It is also unique in its way that it not only kills resistant pathogens (Bacteria) but also prevents the spread of resistance.

The company is positioning ELORES as the need of the hour as it would be able to reduce a minimum of 30% of the hospitalization cost and almost 50% of the drug cost, thereby proving to be very beneficial for the patients.

Venus Remedies is a pharmaceutical manufacturing company. The company provides formulations in area of antibiotics and oncological therapeutics. The company has two manufacturing facilities located in India and Germany. It manufactures Oncological and Cefelosporine Injectable products.

Venus Remedies Share Price

745.20 -7.70 (-1.02%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×